Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.

RenJi Hospital43 enrolled

Overview

Epithelial ovarian cancer constitutes one of the most common gynecological malignancies.Because the ovaries lie in the deep pelvic cavity,most ovarian cancer patients are asymptomatic, rendering the majority often diagnosed at an advanced stage.ctDNA in cancer patients often bears similar genetic and epigenetic features to the related tumor DNA.This study aims to detect plasma ctDNA in Diagnosis of Epithelial Ovarian Cancer.

Epithelial ovarian cancer constitutes one of the most common gynecological malignancies, with an incidence rate of 3-12/100 000 woman per year. Because the ovaries lie in the deep pelvic cavity,most ovarian cancer patients are asymptomatic, rendering the majority often diagnosed at an advanced stage. Liquid biopsy, which is meant to detect cancers by sequencing the DNA in a few drops of a person's blood. It may detect cancers early, even before symptoms arise, when there is just a few cells in the blood circulation. ctDNA in cancer patients often bears similar genetic and epigenetic features to the related tumor DNA. There is evidence that some of the ctDNA originates from tumor tissue. This, and the fact that ctDNA can easily be isolated from the circulation and other body fluids of patients, makes it a promising candidate as a non-invasive biomarker of cancer. This study aims to detect plasma ctDNA in Diagnosis of Epithelial Ovarian Cancer.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Epithelial Ovarian Cancer

Interventions

methylation markers screeningDIAGNOSTIC_TEST

ctDNA extraction from plasma samples;bisulfite-treated DNA;DNA methylation levels by deep sequencing-Sequencing; data analysis

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * people aged 18years to 80years; * Diagnosis of ovarian cancer is confirmed by two Pathologists independently; * Pregnancy tests are negative. Exclusion Criteria: * With other type of malignancies; * someone who refuse to participate the study.

Locations (1)

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Pathological diagnosis of ovarian lumps

Pathological diagnosis of ovarian lumps，including immunohistochemical information and HE staining information.

Time frame: One week after surgery

Secondary Outcomes

sensitivity (true positive rate)

The proportion of persons with disease who have a positive test (positive test results among persons with disease)

Time frame: 2 year

Specificity (true negative rate)

The proportion of persons without disease who have a negative test (negative test results among persons without disease)

Time frame: 2 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.